Established in 2002, JOYLUCKY Group has been focusing on the research and promotion of biotechnology and pharmaceutical health products for a long time. With innovative technology as the core, it integrates industry, academia, and research to create a professional brand. In the fields of biomedicine, immune cells, genetic engineering, medical testing, etc., it has achieved remarkable achievements and was listed as a national high-tech enterprise in 2020.

JOYLUCKY has established a comprehensive marketing system nationwide, with over 3000 high-quality medical and medical professional institutions distributed throughout the country, and its business network covering more than 30 provinces, cities, and autonomous regions. In the pharmaceutical field, JOYLUCKY uses its core enterprise - Zhejiang Aimei Pharmaceutical Co., Ltd. - as a strategic platform for research and sales, continuously exporting high-quality products and services, especially in the fields of pediatrics, central nervous system, and other drugs. For many years, JOYLUCKY has maintained a leading market position in the industry.

In terms of scientific research and academia, JOYLUCKY adheres to an international perspective and established a global medical research center in Europe in 2003. It also collaborates with well-known domestic key universities (Fudan University, Shanghai JiaoTong University, East China University of Science and Technology, China Pharmaceutical University, Central South University, etc.) to carry out industry university research cooperation; Maintain academic cooperation with national first level units such as the Chinese Medical Association, the Chinese Medical Association, and the China Association for the Prevention and Control of Drug Abuse, and effectively promote and implement the system of standardized drug use; We have successively established and improved a medical expert resource library covering the whole country.

In the field of smart healthcare, JOYLUCKY has built a smart healthcare industry platform based on Ningbo Ares Technology Co., Ltd., launched hospital level intelligent medical material solutions, AI intelligent pharmacy operation solutions, and smart ward management solutions, providing safe and efficient intelligent medical service integration systems for medical service institutions at all levels.

In the field of medical testing, JOYLUCKY also adheres to the development strategy of integrating industry, academia, and research. As the first subcellular structural damage detection project developed based on flow cytometry technology platform in China, it is currently at the leading level in the domestic industry.

In 2022, JOYLUCKY Group will layout the Iris Smart Medical Industry Park in Ningbo High tech Zone, with an initial investment of over 600 million yuan. The park will be designed by renowned masters from the Landscape Architecture Design Institute of the Chinese Academy of Fine Arts, with an operating area of 50000 square meters. It plans to build JOYLUCKY International Biomedical Research Center, Smart Medical Equipment Production Center, Cell Medicine Reagent Production and Testing Center, JOYLUCKY Business School, and JOYLUCKY Academician Workstation Related entities such as the JOYLUCKY Medical Industry Alliance.

Strong team execution and corporate cohesion are the guarantees for the sustainable development of JOYLUCKY. We adhere to the corporate spirit of "affinity, responsibility, and efficiency", continuously build the core competitiveness of the enterprise, create a happy enterprise, and strive to achieve the common values of partners, employees, and the enterprise. Never forget our original intention, take public health as our responsibility, and provide high-quality products and services to make people's lives better.